FI962693A - Geeni-ilmentymisen kontrolli - Google Patents
Geeni-ilmentymisen kontrolli Download PDFInfo
- Publication number
- FI962693A FI962693A FI962693A FI962693A FI962693A FI 962693 A FI962693 A FI 962693A FI 962693 A FI962693 A FI 962693A FI 962693 A FI962693 A FI 962693A FI 962693 A FI962693 A FI 962693A
- Authority
- FI
- Finland
- Prior art keywords
- control
- gene expression
- double
- helix
- regions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
- C12N2310/152—Nucleic acids forming more than 2 strands, e.g. TFOs on a single-stranded target, e.g. fold-back TFOs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/532—Closed or circular
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/802—Virus-based particle
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
- Y10S977/916—Gene therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/92—Detection of biochemical
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9315798 | 1993-12-29 | ||
FR9315798A FR2714383B1 (fr) | 1993-12-29 | 1993-12-29 | Contrôle de l'expression de gènes. |
FR9401536 | 1994-12-27 | ||
PCT/FR1994/001536 WO1995018223A1 (fr) | 1993-12-29 | 1994-12-27 | Controle de l'expression de genes |
Publications (3)
Publication Number | Publication Date |
---|---|
FI962693A true FI962693A (fi) | 1996-06-28 |
FI962693A0 FI962693A0 (fi) | 1996-06-28 |
FI120740B FI120740B (fi) | 2010-02-15 |
Family
ID=9454520
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI962693A FI120740B (fi) | 1993-12-29 | 1996-06-28 | Menetelmä terapeuttisesti käyttökelpoisen kaksisäikeisen DNA:n valmistamiseksi |
Country Status (16)
Country | Link |
---|---|
US (1) | US6133024A (fi) |
EP (2) | EP0737248B1 (fi) |
JP (1) | JPH09507387A (fi) |
AT (1) | ATE378405T1 (fi) |
AU (1) | AU1388495A (fi) |
CA (1) | CA2180032C (fi) |
DE (1) | DE69435043T2 (fi) |
DK (1) | DK0737248T3 (fi) |
ES (1) | ES2297830T3 (fi) |
FI (1) | FI120740B (fi) |
FR (1) | FR2714383B1 (fi) |
IL (1) | IL112195A (fi) |
NO (1) | NO962707L (fi) |
PT (1) | PT737248E (fi) |
WO (1) | WO1995018223A1 (fi) |
ZA (1) | ZA9410367B (fi) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
NZ547283A (en) | 1998-03-20 | 2008-06-30 | Commw Scient Ind Res Org | Control of gene expression |
US6525185B1 (en) | 1998-05-07 | 2003-02-25 | Affymetrix, Inc. | Polymorphisms associated with hypertension |
JPH11335269A (ja) | 1998-05-19 | 1999-12-07 | Hisamitsu Pharmaceut Co Inc | 遺伝子関連医薬の経口投与固形製剤 |
EP1147204A1 (en) * | 1999-01-28 | 2001-10-24 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
WO2000063364A2 (en) * | 1999-04-21 | 2000-10-26 | American Home Products Corporation | Methods and compositions for inhibiting the function of polynucleotide sequences |
US20040138168A1 (en) * | 1999-04-21 | 2004-07-15 | Wyeth | Methods and compositions for inhibiting the function of polynucleotide sequences |
US6423885B1 (en) | 1999-08-13 | 2002-07-23 | Commonwealth Scientific And Industrial Research Organization (Csiro) | Methods for obtaining modified phenotypes in plant cells |
EP1229134A3 (en) * | 2001-01-31 | 2004-01-28 | Nucleonics, Inc | Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell |
FR2822476B1 (fr) | 2001-03-23 | 2004-04-02 | Aventis Pharma Sa | Procedes de purification et de detection de sequences cibles d'adn double brin par interaction triple helice |
US20050075298A1 (en) * | 2002-01-31 | 2005-04-07 | Wei Chen | Methods and composition for delivering nucleic acids and/or proteins to the intestinal mucosa |
US20040043003A1 (en) * | 2002-01-31 | 2004-03-04 | Wei Chen | Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions |
US20040009937A1 (en) * | 2002-01-31 | 2004-01-15 | Wei Chen | Methods and composition for delivering nucleic acids and/or proteins to the respiratory system |
EP1572902B1 (en) | 2002-02-01 | 2014-06-11 | Life Technologies Corporation | HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES |
US20040014956A1 (en) | 2002-02-01 | 2004-01-22 | Sequitur, Inc. | Double-stranded oligonucleotides |
US20060009409A1 (en) | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
DE202005004135U1 (de) * | 2005-03-11 | 2005-05-19 | Klocke Verpackungs-Service Gmbh | Mehrkomponentenverpackung mit Applikator |
CA2825894C (en) | 2011-02-02 | 2021-11-30 | Amgen Inc. | Prognosis of cancer using a circulating biomarker |
AU2012335541B2 (en) | 2011-11-11 | 2017-07-06 | Duke University | Combination drug therapy for the treatment of solid tumors |
US8980259B2 (en) | 2012-07-20 | 2015-03-17 | Novartis Ag | Combination therapy |
WO2017129763A1 (en) | 2016-01-28 | 2017-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5399676A (en) * | 1989-10-23 | 1995-03-21 | Gilead Sciences | Oligonucleotides with inverted polarity |
FR2675803B1 (fr) * | 1991-04-25 | 1996-09-06 | Genset Sa | Oligonucleotides fermes, antisens et sens et leurs applications. |
WO1993012230A1 (en) * | 1991-12-13 | 1993-06-24 | Sri International | Triple-helix formation at (punpyn).(punpyn) tracts |
FR2687411A1 (fr) * | 1992-02-13 | 1993-08-20 | Nice Sophia Antipolis Universi | Vecteur comportant un gene viral transcrit par l'arn polymerase iii, et procede de production intracellulaire d'arn. |
US5624803A (en) * | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
US5700657A (en) * | 1993-12-13 | 1997-12-23 | Genzyme Corporation | Vectors and vector systems including genes encoding tumor suppressor proteins and producer cells transformed thereby |
-
1993
- 1993-12-29 FR FR9315798A patent/FR2714383B1/fr not_active Expired - Lifetime
-
1994
- 1994-12-27 EP EP95905172A patent/EP0737248B1/fr not_active Expired - Lifetime
- 1994-12-27 CA CA2180032A patent/CA2180032C/fr not_active Expired - Lifetime
- 1994-12-27 ES ES95905172T patent/ES2297830T3/es not_active Expired - Lifetime
- 1994-12-27 JP JP7517818A patent/JPH09507387A/ja not_active Ceased
- 1994-12-27 PT PT95905172T patent/PT737248E/pt unknown
- 1994-12-27 WO PCT/FR1994/001536 patent/WO1995018223A1/fr active IP Right Grant
- 1994-12-27 AU AU13884/95A patent/AU1388495A/en not_active Abandoned
- 1994-12-27 DE DE69435043T patent/DE69435043T2/de not_active Expired - Lifetime
- 1994-12-27 AT AT95905172T patent/ATE378405T1/de active
- 1994-12-27 DK DK95905172T patent/DK0737248T3/da active
- 1994-12-27 EP EP07007057A patent/EP1939290A3/fr not_active Withdrawn
- 1994-12-28 ZA ZA9410367A patent/ZA9410367B/xx unknown
- 1994-12-29 IL IL11219594A patent/IL112195A/en not_active IP Right Cessation
-
1996
- 1996-06-26 NO NO962707A patent/NO962707L/no not_active Application Discontinuation
- 1996-06-28 FI FI962693A patent/FI120740B/fi not_active IP Right Cessation
-
1998
- 1998-05-07 US US09/074,357 patent/US6133024A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JPH09507387A (ja) | 1997-07-29 |
FI962693A0 (fi) | 1996-06-28 |
IL112195A (en) | 2004-08-31 |
US6133024A (en) | 2000-10-17 |
FR2714383B1 (fr) | 1996-02-09 |
NO962707D0 (no) | 1996-06-26 |
EP0737248A1 (fr) | 1996-10-16 |
EP0737248B1 (fr) | 2007-11-14 |
DK0737248T3 (da) | 2008-03-25 |
ZA9410367B (en) | 1995-09-20 |
DE69435043T2 (de) | 2008-09-04 |
ES2297830T3 (es) | 2008-05-01 |
AU1388495A (en) | 1995-07-17 |
NO962707L (no) | 1996-06-26 |
FR2714383A1 (fr) | 1995-06-30 |
EP1939290A3 (fr) | 2011-07-06 |
CA2180032A1 (fr) | 1995-07-06 |
PT737248E (pt) | 2008-02-25 |
WO1995018223A1 (fr) | 1995-07-06 |
EP1939290A2 (fr) | 2008-07-02 |
IL112195A0 (en) | 1995-03-15 |
CA2180032C (fr) | 2010-08-10 |
DE69435043D1 (de) | 2007-12-27 |
FI120740B (fi) | 2010-02-15 |
ATE378405T1 (de) | 2007-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI962693A0 (fi) | Geeni-ilmentymisen kontrolli | |
ATE171210T1 (de) | Selbststabilisierte oligonukleotide als therapeutika | |
EP1156108A3 (en) | Use of exo-sample nucleotides in gene cloning | |
DE69636080D1 (de) | Eine in Kaskaden verlaufende Vervielfältigungsreaktion von Nukleinsäuren | |
ATE225369T1 (de) | Doppelsträngige peptidenukleinsäuren | |
DE69514773D1 (de) | Chimärisches Oligonukleotid und dessen Verwendung zur Herstellung von Nukleinsäure-Transkripten | |
ES2108748T3 (es) | Amplificacion de acidos nucleicos con actividad de rna polimerasa dependiente de dna, de rna replicasas. | |
WO1996001314A3 (de) | Ribozym-bibliothek, ihre herstellung und ihre verwendung | |
HK1001131A1 (en) | Method for detecting a target nucleic acid | |
DE60023480D1 (de) | Amplifikation und sequenzierung von primer-paaren und deren verwendung | |
AU6144294A (en) | Plant virus resistance conferring polyribozyme and resistant plants producing same | |
EE03074B1 (et) | Rekombinantsed eukarüootsed rakud, nende saamiseks vajalikud DNA järjestused, meetod eukarüootsete rakkude konstrueerimiseks ja sekreteeritavate valkude ning biomassi tootmismeetod | |
DE50209094D1 (de) | Vermehrung von ribonukleinsäuren | |
AU2001287860A1 (en) | Transglutaminase gene products | |
EP1312677A4 (en) | NUCLEIC ACIDS ENCODING PROTEINS OF LETTUCE VEGETABLE HYPERTROPHY VIRUSES AND USE THEREOF | |
ATE296883T1 (de) | Mn-gen und -protein | |
WO1999053082A3 (en) | Hexose carrier proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Patent granted |
Ref document number: 120740 Country of ref document: FI |
|
MA | Patent expired |